as an investigator on clinical trials sponsoredby Eli Lilly and Amylin Pharmaceuticals; is an advisory board member for Eli Lilly, Novo Nordisk, GlaxoSmithKline, and Takeda; andhas received education grant support fromEli Lilly. R.M.C. has served as an investigator on clinical trials sponsored by Amylin, Ab- bott, Bayer, Calibra Medical, Daiichi-Sankyo,Dexcom, Edwards Lifesciences, Eli Lilly, Hygeia,Intarcia, Johnson & Johnson, MannKind,Medtronic, Merck, Novo Nordisk, Quotient Diagnostics, ResMed, Roche, sano ﬁ-aventis, Schering-Plough, Takeda, and Valeritas. R.M.C. was an advisory board member for Abbott, Bayer, Eli Lilly, Novo Nordisk, and Roche andhas received education grant support fromJohnson & Johnson, Eli Lilly, Merck, No- vartis, sano ﬁ-aventis, and Schering-Plough. All honoraria, speaking fees, consulting fees, andresearch and educational support were paiddirectly to the nonpro ﬁt International Diabetes Center, of which R.M.C. was a salaried em-